Sedar updates for those that want the cliff notes, just a couple things I noticed:
1. Lots of options being granted to employees over the past year, almost 11M, not including the 8.325M granted to David Jan 2017. Perhaps they are taking less in salary and more in options? I’m ok with that I guess as it should continue their drive towards commercialization. No salaries were listed...
2. It appears they, so far anyway, have been over estimating the recent Milestone costs:
Q4 2017 estimated cost was $5.9M, actual $1.9M
Q1 2018 est cost was $10M, not sure why they don’t have a confirmed updated actual but it appears they would be at $9.7M or less.
Q2 est was $9.5M and revised est is now $4.6M through June.
It would appear then that they have enough cash on hand to likely get into Jan/Feb, since actual costs are less, so far a way...
3. $12.7M est for Q1 2019 Milestone 5.
4. FDA draft Q submission scheduled for Q2 2019, design freeze still shows second half of 2019 along with regulatory submission. All of those costs still TBD, but estimate a minimum of $50M still needed through early commercialization.
Anyone find anything else to update us all on?